OPSUMIT®

(macitentan)

Endothelin receptor antagonist

JOHNSON & JOHNSON (HONG KONG) LTD

HK Reg. No. HK-69121 (02 Jun, 2026)

Composition4:

OPSUMIT ® is available as 2.5 mg dispersible tablets

Indication4:

OPSUMIT®, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in paediatric patients aged 2 years to less than 18 years with WHO Functional Class (FC) II to III

References

1. Drug office. DATROWAY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG. Available from: https://www.drugoffice.gov.hk/eps/drug/productDetail/en/pharmaceutical_trade/160525. [Accessed 12 August 2026]. 2. Drug office. CAPVAXIVE 21-VALENT PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE IN PRE-FILLED SYRINGE 0.5ML. Available from: https://www.drugoffice.gov.hk/eps/drug/productDetail/en/pharmaceutical_trade/160367. [Accessed 12 August 2026]. 3. Drug Office. TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100U/ML 3ML. Available from: https://www.drugoffice.gov.hk/eps/drug/productDetail/en/pharmaceutical_trade/160528. [Accessed 12 August 2026]. 4. OPSUMIT 2.5MG Hong Kong Prescribing Information.